SHENZHEN, China, March 16, 2025 /PRNewswire/ -- On March 15, the globally renowned obstacle racing event, the Spartan Race, kicked off its 2025 season at Bijiashan Park in the downtown of southern China's Shenzhen city.
This thrilling event features the Kids Race on March 15 and 16, followed by the Sprint, Super, and the intense 4-hour Hurricane Heat for adults on March 22 to 23. Additionally, the Tough Mudder Kids event will take place at the same venue on April 19.
These international sports events, hosted in downtown Shenzhen's parks and business districts, will inject fresh energy and urban charm into the city and the Greater Bay Area.
Urban Park Life: Enhancing Accessibility and Diversity
Since its debut in the United States in 2010, the Spartan Race has captivated the world with its demanding courses and diverse events, now held in over 40 countries and regions. The first day of the exciting Kids Race drew over 6,500 young participants.
Bijiashan Park, the race venue, is centrally located in Shenzhen. Adjacent to the UpperHills urban complex, the park is a beloved spot for sports and leisure among locals and a key component of Shenzhen's Five-park Connectivity Plan, exemplifying the city's "Park + Business" model.
UpperHills Fashion Life: Delight in Two Spectacular Flower Shows
As a key partner of the race, UpperHills utilizes its distinctive business model featuring "town, shopfront and mall" to deliver comprehensive services for the event.
During the event, UpperHills will serve as a rest area for participants and spectators, hosting a range of cultural and leisure activities. It will debut the International Exotic Plants Show & Sale from March 28 to 30. Furthermore, the Greater Bay Area Flower Show 2025 is set to take place from March 28 to April 6 at Bijiashan Sports Park-UpperHills.
As a premier international urban complex in Shenzhen and a key cultural hub in the Greater Bay Area, UpperHills is at the forefront of creating diverse consumer experiences. Through a vibrant array of international cultural and sports events, it plays a pivotal role in elevating Shenzhen as a global hotspot for sports, culture, and commerce. This initiative supports the city's ambition to become an international consumption center, offering exciting new opportunities and experiences for global visitors.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
UpperHills: The 2025 Spartan Race Elevating Shenzhen's Status as an International Consumption Hub
YONGIN, South Korea, March 21, 2025 /PRNewswire/ -- Noul Co., Ltd. a Korea-based medical AI company, announced that it presented a poster titled "Bridging Medical Gaps from Malaria to Cancer: On-Device AI Diagnostic Solutions Powered by NVIDIA Jetson" at NVIDIA GTC 2025, the world's leading AI developer conference. The presentation highlights Noul's AI-powered diagnostic platform miLabâ„¢ CER, an innovative on-device solution for cervical cancer screening.
As part of this milestone, Noul has also officially joined the NVIDIA Healthcare & Life Sciences (HCLS) partner ecosystem, expanding its collaboration to advance the role of AI in global healthcare delivery.
The poster presentation addressed diagnostic challenges in underserved regions, emphasizing how miLab, Noul's AI-embedded, fully automated diagnostic platform, overcomes barriers to access — not only in low- and middle-income countries but also in highly centralized healthcare systems in developed nations. Cervical cancer, which ranks as the third leading cause of cancer-related deaths among women globally, remains a critical yet preventable disease with limited access to screening in many regions.
"We're proud to present our AI diagnostic solution for cervical cancer at GTC 2025," said David Lim, CEO of Noul Inc. "miLabâ„¢ is the world's first commercialized, fully automated digital microscope for real-time, on-site diagnostics without relying on cloud infrastructure. Powered by Noul's proprietary, cloud-independent diagnostic technology, miLab is poised to significantly enhance global healthcare accessibility."
Noul's miLab™ platform is a compact bench-top diagnostic device that automates sample staining, digital imaging, embedded deep learning, and AI-powered result analysis — delivering test results in just 15 minutes. The system is powered by NVIDIA Jetson, which significantly enhances AI inference performance and supports scalable diagnostics across various disease areas.
The cervical cancer solution featured in the presentation, miLabâ„¢ CER, was previously recognized by WHO-UNITAID in 2024 as one of the Top 3 global diagnostic products alongside solutions from Roche and Hologic.
GTC 2025, hosted by NVIDIA from March 17–21 in San Jose, California, brings together over 25,000 in-person attendees and more than 300,000 online participants. The event features groundbreaking developments in agentic AI, physical AI, scientific discovery, and accelerated computing. NVIDIA Founder and CEO Jensen Huang will deliver the keynote highlighting how AI is transforming industries and reshaping the future.
About Noul Co., Ltd.
"Enabling blood and cancer diagnostics anywhere in the world through AI technology."
Noul Co., Ltd. (376930.KQ) is an on-device AI healthcare company founded in December 2015 with the mission: "We explore global challenges that threaten human health and life, discover novel potential solutions, and realize those possibilities. " By combining expertise across medical AI, biotechnology, and embedded systems, Noul has commercialized miLabâ„¢, the world's first AI-powered diagnostic lab platform for point-of-care settings.
miLab™ is a fully automated blood and cancer diagnostic solution that delivers lab-grade accuracy and convenience at the point of care. It automates the entire microscopy workflow—from sample preparation and staining to digital imaging and AI analysis—providing precise diagnostic results in under 15 minutes.
Recognized globally for its technological innovation, miLab was featured in the 2022 Unitaid Report as "The Most Advanced Digital Microscope and Fully Integrated Bench-top Platform" for microscopy-based diagnostics. In the 2024 WHO-Unitaid report, Noul's AI-based cervical cytology product, miLabâ„¢ CER, was recommended as one of the Top 3 global solutions for cervical cancer triage diagnostics alongside products from Roche and Hologic.
Backed by strong clinical evidence and technical performance, miLab continues to build global trust. Following the successful launch of its AI-based malaria diagnostic solution, Noul has expanded its product line to include blood cell analysis and cervical cancer screening, accelerating its entry into key global markets. miLab is currently used in 18 countries worldwide by pharmaceutical companies, hospitals, diagnostic labs, and government health institutions.
Noul's vision is to improve access to healthcare by delivering impactful products and services that can positively influence the lives of over 1 billion people worldwide, particularly in the fields of blood and cancer diagnostics.
Website: https://noul.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Noul Showcases AI-Powered Cervical Cancer Cell Screening Technology at NVIDIA GTC 2025
